These data are translationally relevant because they suggest that the start of a PARP inhibitor therapy in a clinical setting (in the paradigm of therapeutic repurposing) can be delayed to later time points at which the diagnosis of ALI is confirmed, and the inhibitor may provide benefit even with delayed administration. The gene discussed is PARP1; the disease is acute respiratory distress syndrome.